LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NTRB
Nutriband Inc.
There isn't enough reported data to score NTRB yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NTRB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
NTRB's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NTRB PE Valuation
NTRB has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NTRB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect NTRB's losses to shrink, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus NTRB down 170%.
NTRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.90 | -$0.13 |
| Q1 2025 | -$0.99 | -$0.30 |
| Q4 2024 | -$0.71 | -$0.07 |
| Q3 2024 | -$0.81 | -$0.25 |
| Q2 2022 | -$0.84 | -$0.43 |
| Q1 2022 | -$0.80 | -$0.36 |
| Q4 2021 | -$0.67 | -$0.42 |
| Q3 2021 | -$0.45 | -$0.09 |
NTRB lost $0.57 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NTRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NTRB on profitability, with a higher operating margin.
NTRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $437.5K | -30% |
| Q2 2026 | $433.4K | -35% |
| Q1 2026 | $400.7K | -38% |
| Q4 2025 | $346.1K | -46% |
| Q3 2025 | $622.5K | +41% |
| Q2 2025 | $667.4K | +63% |
| Q1 2025 | $642.4K | +22% |
| Q4 2024 | $645.8K | +51% |
NTRB's revenue has slid since its 2025 peak: $437,514 last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -204% | +118 points |
| Q2 2026 | -289% | -78 points |
| Q1 2026 | -255% | +611 points |
| Q4 2025 | -1121% | -900 points |
| Q3 2025 | -322% | -3.5 points |
| Q2 2025 | -212% | +251 points |
| Q1 2025 | -865% | -616 points |
| Q4 2024 | -221% | +182 points |
NTRB's operating margin was −204% last quarter, up 118 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with NTRB at down 71%.
NTRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$731.8K | +$507.4K |
| Q4 2025 | -$1.8M | -$695.9K |
| Q3 2025 | -$1.3M | +$269.3K |
| Q2 2025 | -$1.3M | -$502.2K |
| Q1 2025 | -$1.2M | -$471.9K |
| Q4 2024 | -$1.1M | +$7.7K |
| Q3 2024 | -$1.6M | -$587.5K |
| Q2 2024 | -$840.1K | -$87.6K |
NTRB has burned cash in almost every quarter: −$5M over the past year, against −$5M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NTRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NTRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +9.3% | +1M shares |
| 3 years | +44% | +3.7M shares |
| 5 years | +84% | +5.6M shares |
| Available history | +92% | +5.8M shares |
NTRB has 12M diluted shares, up 9.3% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NTRB Net Leverage
NTRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NTRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 48.5 | Neutral |
NTRB's weekly RSI is 55 (neutral) and its Stochastic is 48 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NTRB PE vs Healthcare Sector
NTRB has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NTRB on trend strength, trading above more of its moving averages.
NTRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.47 | 7.7% below |
| 20 week MA | $5.16 | 16% above |
| 50 week MA | $4.51 | 32% above |
| 100 week MA | $5.54 | 7.8% above |
| 200 week MA | $4.69 | 27% above |
NTRB's trend is up, with a small recent dip: it's below only its 8-week average, and 27% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NTRB on returns for 2026, with the stronger performance.
NTRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $5.74 | $3.10 | -46% |
| 2022 | $3.10 | $3.59 | +16% |
| 2023 | $3.59 | $2.32 | -35% |
| 2024 | $2.32 | $3.85 | +66% |
| 2025 | $3.85 | $4.80 | +25% |
| 2026 YTD | $4.80 | $5.97 | +24% |
NTRB has finished higher in three of the last five years. It's up 24% so far in 2026.